Venom protein that mimics the incretin hormone glucagon-like peptide 1 (GLP-1). It stimulates insulin synthesis and secretion, protects against beta-cell apoptosis in response to different insults, and promotes beta-cell proliferation. It also promotes satiety, reduces food intake, reduces fat deposition, reduces body weight and inhibits gastric emptying. Interacts with GLP-1 receptor (GLP1R). Induces hypotension that is mediated by relaxation of cardiac smooth muscle. Expressed by the venom gland. Available under the name Byetta and Bydureon (extended-release exenatide) (Amylin Pharmaceuticals). Used for the treatment of type 2 diabetes. Enhances insulin secretion in response to elevated plasma glucose levels. Belongs to the glucagon family.